First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M.
Vaccaro V, et al. Among authors: gelibter a.
World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511.
World J Gastroenterol. 2013.
PMID: 23901226
Free PMC article.
Clinical Trial.